At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 116 enrolled
Drug / intervention
Blinatumomabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Confirmatory Multicenter, Single-arm Study to Assess the Efficacy, Safety, and Tolerability of the BiTE® Antibody Blinatumomab in Adult Patients With Minimal Residual Disease (MRD) of B-precursor Acute Lymphoblastic Leukemia (BLAST)
In Brief
A Phase 2 clinical trial evaluating Blinatumomab for B-cell Acute Lymphoblastic Leukemia. Completed, enrolled 116 participants across 75 sites in 11 countries.
Detailed Summary
The purpose of this study is to confirm whether the bispecific T cell engager blinatumomab (MT103) is effective, safe and tolerable in the treatment of ALL patients with minimal residual disease.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsB-cell Acute Lymphoblastic Leukemia
CountriesAustria, Belgium, France, Germany, Italy, Netherlands, Poland, Romania, Russia, Spain, United Kingdom
Collaborators--
Timeline
Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedSep 2010
Enrollment StartNov 2010
Primary CompletionFeb 2014
Study CompletionJan 2019
TodayJul 2026
First PostedSep 22, 2010
Enrollment StartNov 1, 2010
Primary CompletionFeb 1, 2014
Study CompletionJan 7, 2019
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 15.8 years ago
Interventions
Blinatumomabdrug
Continuous intravenous infusion